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Laboratory-based surveillance ofLymedisease in Connecticut during 1984 and 1985 identified
3,098 persons with suspected Lyme disease; 1,149 were defined as cases. Lyme disease incidence
in Connecticut towns ranged from none to 1,407 cases per 100,000 population in 1985. A
comparison of 1985 data with data from 1977 epidemiologic studies indicated that incidence
increased by 129 percent to 453 percent in towns previously known to be endemic for Lyme
disease and that Lyme disease had spread northward into towns thought to be free of Lyme
disease in 1977. Children aged five to 14 years had the highest incidence. Of persons with Lyme
disease, 83 percent had erythema migrans, 24 percent had arthritis, 8 percent had neurologic
sequelae, and 2 percent had cardiac sequelae. The distribution of symptoms was age-dependent:
case-persons <20 years old were almost twice as likely to have arthritis than older case-persons
(35 percent versus 18 percent). Of persons with arthritis, 92 percent of those <20 years of age,
compared to 68 percent ofolder persons, did not haveantecedent erythema migrans. Weconclude
that Lyme disease is increasing in incidence and geographic distribution in Connecticut. Ofthose
with Lyme disease, children may be more likely than adults to develop arthritis and have it as
their first major disease manifestation.
Lyme disease, discovered in 1975 in Connecticut, is now endemic in at least 19
countries and 24 states and is the most commonly reported anthropod-related disease
in the United States [1,2]. It is caused by a spirochete, Borrelia burgdorferi, that is
transmitted to humans by ixodid ticks [3,41. Three clinical stages can occur. The first
stage typically begins three to 32 days after a tick bite with a characteristic skin lesion,
erythema migrans [5-7]. Nonspecific symptoms, such as myalgias, headache, fever,
fatigue, and arthralgias, often accompany the skin lesions. The second stage begins
weeks to months later with the development ofneurologic [8,9] or cardiac manifesta-
tions [10,11]. The third stage is characterized by arthritis weeks to years after the
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initial tick bite [4,5]. The second and third stages may occur without the clinical
manifestations ofthe earlier stage.
Epidemiologic studies of Lyme disease have been difficult to conduct, in part
because erythema migrans is the only unique clinical manifestation of Lyme disease
and, consequently, accurate case ascertainment can be difficult to establish based on
clinical criteria alone for persons with cardiac, neurologic, or arthritic manifestations,
especially without antecedent erythema migrans. Indirect immunofluorescence assays
(IFA) and enzyme-linked immunosorbent assays (ELISA) now exist for detecting
antibodies to Borrelia burgdorferi [12,13]. Because these tests have a sensitivity
approaching 100 percent during the secondary and tertiary stages of Lyme disease,
stages when the disease can be the most difficult to diagnose, more complete case
ascertainment is now possible [13,14]. The specificities of the IFA and ELISA tests
are high: of ten healthy controls and 30 persons with rheumatoid arthritis, systemic
lupus erythematosus, orinfectious mononucleosis who weretested by ELISA [13], and
of 40 healthy controls and 51 persons with unknown febrile illness tested by both
ELISA and IFA [14], none were positive for antibodies to Borrelia burgdorferi.
Although cross-reactivity occurs with tick-borne relapsing fever, louse-borne relapsing
fever, syphilis, yaws, and Rocky Mountain spotted fever [15], these diseases are
usually easily distinguished from Lyme disease on the basis ofclinical orepidemiologic
findings.
From July 1984 to March 1986, we studied Lyme disease in Connecticut using a
laboratory-based surveillance system. Our objectives were to determine the frequen-
cies ofthe most common clinical manifestations, thedescriptive epidemiology ofLyme
disease in Connecticut, especially its geographic distribution, and the sensitivity ofthe
serologic test during early Lyme disease as determined by a surveillance system. The
findings ofthis study are the subject ofthis report.
METHODS
Case Ascertainment and Reporting
Serologic testing for Lyme disease has been available to patients of Connecticut
physicians since 1983 from the Connecticut Agricultural Experiment Station. In the
spring of 1984, three announcements from the Connecticut State Department of
Health Services were mailed to all general internists, internal medicine subspecialists,
general pediatricians, pediatric subspecialists, family practitioners, and neurologists
licensed to practice in Connecticut to inform them about Lyme disease and to spread
the word further about the availability offree serologic testing for all suspected Lyme
disease cases. Physicians were required to complete a case report form with all
specimens submitted for testing from July 1, 1984, to March 1, 1986. In addition,
physicians were asked to report voluntarily suspected cases of Lyme disease from
whom serologic testing was not sought. The case report form included information
about the patient's demographic characteristics, detailed clinical history, and history
oftick bite. Information about thepatient's race, number and sizeoferythema migrans
lesions, constitutional symptoms, and specific joint involvement, and the specialty of
the referring physician was obtained only for persons reported in 1984.
Only Connecticut residents with onset ofillness in 1984 or 1985 were included in the
analyses reported here. To meet the case definition, a resident had to have either
erythema migrans or to have neurologic [8,9], cardiac [10,11], or arthritic [4,5]
manifestations consistent with Lyme disease and at least one positive serologic test
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result. Persons with erythema migrans who had reported neurologic, cardiac, or
arthritic symptoms and a negative serologic test result were considered to have
erythema migrans as their only Lyme disease manifestation. This distinction was
primarily made to minimize misclassifying arthralgia as arthritis. Arthralgia fre-
quently occurs in early Lyme disease when the serology is often negative, whereas
arthritis, which occurs later, is almost always accompanied by a positive serology.
Persons with a positive serologic test but without erythema migrans, and without
cardiac, neurologic, or arthritic manifestations were not counted as cases.
Although information submitted on the case report form was not systematically
validated, the medical chartsof72 persons with erythema migrans and 29 persons with
arthritis reported as part of this surveillance study in 1984 were reviewed in 1987.
Ninety-four percent ofpatients with erythema migrans and 93 percent ofpatients with
arthritis had sufficient information recorded in the medical chart to confirm these
diagnoses [16].
Long-term changes in Lyme disease incidence were assessed by comparing 1977
incidences for residents ofnine towns west ofthe Connecticut River (Chester, Clinton,
Deep River, Essex, Haddam, Killingworth, Madison, Old Saybrook, and Westbrook)
[17] and three towns east of the Connecticut River (East Haddam, Lyme, and Old
Lyme) [17] to the 1985 incidences found in this study. The study conducted in 1977
utilized an active surveillance system where all physicians in the study communities
were contacted in person and by telephone. Although the case definition used in the
1977 study was similar tothat used in 1984-1985, serologic testing was not available in
1977 to confirm the diagnosis of Lyme disease in those with neurologic, cardiac, or
arthritic manifestations. Misclassification of patients with arthritis in 1977 was
minimized, however, because patients were required to have laboratory and clinical
evidence that should have excluded other causes ofarthritis.
Serological Assay
All serum samples were tested by IFA or ELISA with a polyvalent conjugate using
methods described elsewhere [15,18-20]. Serum samples received before July 1985
were tested by IFA; sera received later were analyzed by ELISA. In a preliminary
study of 139 patients with erythema migrans reported in 1984, both tests had 95
percent concordance when identical paired sera were tested [20]. For this study, a titer
of .1:128 by IFA or >1:160 by ELISA was considered positive. Because as many as
three serum samples weresubmitted for some patients, persons wereconsidered to have
a positive serologic test result ifany sample was positive.
Data Analysis
The data were analyzed using the Statistical Analysis System program [211.
Univariate analyses were performed using the chi-square test. Age-specific population
estimates werederived from 1984 data in theConnecticut AnnualRegistration Report
ofVital Statistics, 1985 [22]. Because the Registration Report did not contain yearly
population estimates by town ofresidence, data from the 1980 U.S. Census were used
for computation of 1984 and 1985 Lyme disease incidence by town ofresidence.
RESULTS
Of the 3,098 persons reported with possible Lyme disease, 1,149 (37 percent) were
defined as cases. Of these, 460 had onset of symptoms in 1984 and 689 in 1985. The
percentages of persons reported with possible Lyme disease who met our case
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FIG. 1. Lyme disease cases by month ofinitial symptom onset: Connecticut, 1985.
definition were similar in 1984 (36 percent; 460/1,290) and 1985 (38 percent;
689/1,808). In 1984, over 75 percent of case-persons were reported by primary care
physicians: family practice (40 percent), internal medicine (20 percent), and pediatrics
(16 percent). The remainder were reported by specialists in rheumatology (9 percent),
dermatology (3 percent), infectious disease (2 percent), neurology (1 percent), or other
fields (7 percent).
Epidemiologic Features
In 1985, the first complete year of reporting, 66 percent (408) of 619 case-persons
with known month of onset had onsets in June, July, and August (Fig. 1). When
comparisons in Lyme disease incidence were limited to those with onset of symptoms
from July to December, time periods during both reporting years when serologic
testing was equally available, a 24 percent increase was observed from 1984 (397) to
1985 (492).
Estimated Lyme disease incidence for all Connecticut residents was 22/100,000 in
1985. Because the geographic location where the tick bite occurred was often
dnknown, town-specific incidences were computed by town ofresidence. Lyme disease
was sharply demarcated in geographic distribution. In 1985, Lyme disease incidence
for Connecticut towns ranged from zero to 1,156/100,000, and every town with an
incidence >300/100,000 population was located within 40 kilometers ofanother town
where Lyme disease was not reported (Fig. 2). High-incidence towns were located in
southeastern Connecticut and in the lower Connecticut River Valley. Almost half (48
percent) of towns with an incidence of 1-49/100,000 had only one case-resident.
Compared to 1977 data, the 1985 incidence increased by 129 percent (280/100,000 to
650/100,000) in three towns east of the Connecticut River, and by 453 percent
(13/100,000 to 73/100,000) in eight towns west ofthe River.
Fifty-one percent (585/1,149) ofpersons with Lyme disease were male. All but one
of the 372 case-persons reported in 1984 whose race was specified were white.
Age-specific Lyme disease incidence was tabulated by five-year age groups for those
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FIG 2. Lyme disease incidence by town ofresidence: Connecticut, 1985.
with symptom onset in 1985. Incidence ranged from 11/100,000 for persons aged 20 to
24 years to 39/100,000 for those aged five to nine years (Fig 3).
Clinical Features
Overall, 911 (83 percent) of those with Lyme disease had erythema migrans, 252
(24 percent) had arthritis, 84 (8 percent) had neurologic manifestations, and 22 (2
percent) had cardiac involvement (Table 1). Data about the number and size of
erythema migrans skin lesions were available for 285 persons reported in 1984: 31
percent (89/285) had two or more erythema migrans lesions; the median size of the
largest lesion was 10 centimeters, with a range of 1 to 45 centimeters. Information
about specific joint involvement was available for 44 of 49 persons with arthritis
reported during 1984. Affected joints were the knee (89 percent), hip (9 percent),
shoulder (9 percent), ankle (7 percent), and elbow (2 percent).
The distribution of some symptoms was age-dependent. Among those with Lyme
disease, persons <20 yearsold were almost twice as likely tohavearthritis as those .20
years old (Table 2). There was, however, no corresponding increase in frequency of
neurologic or cardiac manifestations in case-persons <20 years old (Table 2). Of
case-persons with arthritis, only 10 percent (11/113) of those <20 years of age had
antecedent erythema migrans, compared to 32 percent (41/129) ofthose >20 years of
age (p < 0.001).
Information about tick bites within 30 days of onset of illness was collected from
1,940 ofthe persons reported with Lyme disease. Persons defined as cases were almost
twice as likely to have a history of tick bite (54 percent, 417/779) than those not
defined as cases (31 percent, 360/1,161). Among case-persons, 60 percent (333/552)
257
... .......
.... ........
... .......
.. .... ......
..... ......
......... ..
.... ..... ........
.... ......
Per 100,000 Popt
0 1-49PETERSEN ET AL.
70
I= 60 i 1 Total Cases
XL I
0 50-
o40
30 / 1 15 20 2 30
FIG 3. Lym disas iniec4yae4fptet onetct95
CwL
C20 /. .
ofthsewihnleytem mgrn6 Atriti ( Erythema Migrans Only
migrans and a~~~~~rthriticnerlgcoradicm ifstiosan26pret(31)
*o1
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70O'+
Age (in years, by 5-year increments)
FIG. 3. Lyme disease incidence by age ofpatient: Connecticut, 1985.
of those with only erythema migrans, 64 percent (41/64) of those with erythema
migrans and arthritic, neurologic, or cardiac manifestations, and 26 percent (43/163)
of those with arthritic, neurologic, or cardiac involvement but without erythema
migrans, had a history oftick bite. The species ofticks were not identified.
Information about antibiotic therapy was available for 391 case-persons reported in
1984. Three hundred thirty-two persons (85 percent) were treated with tetracycline,
penicillin, or erythromycin, nine persons (2 percent) received other antibiotics, and 50
persons (13 percent) had received no antibiotics as of the date of submission of the
initial case report form.
SerologicStudy
Seventy-two persons were reported without a request for serologic testing in 1984;
therefore, 3,026 (98 percent) of 3,098 reported persons had at least one serologic test.
Ofthose with serologic tests, 37 percent (1,117) had two specimens and 3 percent (86)
had three specimens submitted for testing. Specimens from 1,447 persons were
analyzed by IFA, and specimens from 1,579 persons were analyzed by ELISA.
Neither the IFA nor the ELISA was sensitive during the early stages ofdisease. The
positivity rate for the first serum specimen for those with erythema migrans was only
30 percent by IFA and 24 percent by ELISA (Table 3). The sensitivity ofboth the IFA
and the ELISA improved if the serum sample was drawn -21 days after the onset of
illness.
DISCUSSION
Our data indicate that Lyme disease is spreading geographically in Connecticut. In
1977, epidemiologic studies in Connecticut showed that Lyme disease occurred almost
exclusively in towns located near the shoreline and east of the Connecticut River
[15,23], areas where the tick vector, I. dammini, was abundant [24]. By 1983,
entomologic and serologic studies suggested that the geographic distributions of I.
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TABLE 1
Clinical Characteristics of Lyme Disease
Connecticut, 1984-1985
Symptom/Sign No. Reporting' %
Constitutional
Fever 214 57
Myalgia 181 49
Headache 164 44
Arthralgia 126 34
Stiff neck 75 20
Sore throat 39 11
Nausea/vomiting 38 10
Skin rash 938 86
Erythema migrans 911 83
Other rash 94 9
Neurologic 84 8
Bell's palsy 29 3
Encephalitis 14 1
Meningitis 14 1
Cardiac 22 2
Conduction defect 15 1
Arthritic 252 24
aDenominator totals range from 367 to 378 for constitutional
symptoms and from 1,070 to 1,111 for other symptoms and signs
because of persons with unknown symptom history. Constitutional
symptom information was gathered only in 1984.
dammini and human B. burgdorferi infections had extended northward in the
Connecticut River Valley and into northeastern Connecticut [25,26]. By 1985, Lyme
disease was endemic in nearly all towns in southeastern Connecticut; four of these
towns were located >25 kilometers from the shoreline and had incidences >300 per
100,000 population.
Our surveillance data also suggest that the incidenceofLyme disease is increasing in
Connecticut. From 1984 to 1985, the incidence increased by 24 percent. This increase
was probably a conservative estimate, because surveillance was stimulated by physi-
cian notification only in 1984. Physicians may have also realized by 1985 that the
serologic test had low sensitivity during the early stages ofLyme disease and may have
ordered the test less frequently. The percentage ofcase-persons with erythema migrans
TABLE 2
Lyme Disease Clinical Characteristics by Age of Patient
Connecticut, 1984-1985
Age <20 Years Age .20 Years
Characteristic Reported/Total (%) Reported/Total (%) RRa 95% C.I.
Neurologic 27/319 (8) 51/744 (7) 1.2 0.8-2.0
Cardiac 3/210 (1) 17/566 (3) 0.5 0.1-1.7
Arthritic 113/326(35) 129/701 (18) 1.9 1.5-2.3
aRelative risk (RR): risk of characteristic for persons aged <20 years compared to those aged .20
years
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TABLE 3
Detection of Total Immunoglobulin to B. burgdorferi in Initial Serum Samples,
by Time After the Onset of Erythema Migrans
Connecticut, 1984-1985
Time After Onset IFA ELISA
of Erythema Migransa n/Total (%) n/Total (%)
<21 days 59/236 (25) 72/317 (23)
.21 days 31/67 (46) 20/63 (32)
Total 90/303 (30) 92/380 (24)
'The time after symptom onset was unknown for 192 persons, and 36 persons had no serology
obtained.
did not change over both reporting years, suggesting that reporting patterns did not
changeoverall. Nevertheless, theobserved annual rateofincrease is consistent with the
129 percent to 453 percent increases in incidence observed from 1977 to 1985 in
southeastern Connecticut. It is doubtful that the magnitude of this increase could be
accounted for by different surveillance methodologies or case definitions. In fact,
the 1977 study may have had greater case ascertainment because physicians were
telephoned to report cases [17]. Anecdotal reports received by us from physicians with
long-standing practices in Lyme and surrounding communities also suggest that Lyme
disease markedly increased in incidence from 1977 to 1985.
Although the observed Lyme disease incidence was considerable in some towns, our
surveillance system probably underestimated the actual incidence for several reasons:
(I) the system was laboratory-based, so that many persons with erythema migrans, a
unique clinical markerofLymedisease, may not have had serologic testing; (2) persons
with stage one disease who had atypical skin rashes or nonspecific symptoms would not
have been defined as cases, regardless of the serologic test results; (3) the diagnosis of
Lyme disease may not have been considered for those with atypical presentations; and
(4) sera from some Connecticut residents may have been tested at Yale University.
Although the actual number tested at Yale was unknown, a record review of all
patients tested there from July to December 1984 found only seven additional
Connecticut residents who would have met the case definition for this study.
Our data also indicate that there is age-specific variation in Lyme disease incidence
and clinical response toBorrelia burgdorferi infection. Children five to 14 years ofage
had the highest Lyme disease incidence. It is unknown if they had the greatest
exposure to ticks, were more likely todevelop symptoms after infection, or were simply
more likely to be reported. A previous serologic study of a defined island population
suggested that adults were less likely todevelop symptoms after infection than children
[27]. We also found that persons with Lyme disease who were <20 years of age were
more likely to have arthritis as the first manifestation of Lyme disease than were
persons .20 years of age. This finding is supported by the longitudinal study of an
island population that also found that children were more likely to present with
arthritis alone [27].
Serologic tests for Lyme disease have generally been reported to have low or
moderate sensitivityduring stage-one Lymedisease [12-14,28]. In a preliminary study
of 139 patients with erythema migrans, ELISA and IFA tests had comparable
sensitivities, regardless of whether class-specific IgM or polyvalent conjugates were
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used [20]. In our study, the ELISA with a polyvalent conjugate had an overall
sensitivity ofonly 24 percent. This low value could be due to delayed immune response
or to previous antibiotic treatment [28]. Inview ofthe low sensitivities ofserologic tests
during early Lyme disease, it is particularly important for physicians to re-evaluate
clinical data when antibodies are not detected. If necessary, a second or third serum
sample should be obtained to monitor a rise in antibody levels. Serologic testing,
however, remains a valuable diagnostic tool for patients with secondary or tertiary
stages of Lyme disease [13].
ACKNOWLEDGEMENT
The authors thank Carmelle Kennedy for technical assistance with data management; Clifford Snow III,
Pat Trzcinski, and Deborah Shea for assistance in performing serologic tests; and Matt Cartter for his
editorial suggestions.
REFERENCES
1. Ciesielski CA, Hightower AW, Horsley R, Russell H, Markowitz LE, Broome CV: Theepidemiology of
Lyme disease in the United States. In Abstracts, International Conference on Lyme Disease and
Related Disorders. New York, New York Academy ofSciences, 1987
2. Schmid GP: The global distribution ofLyme disease. Rev Infec Dis 7:41-50, 1985
3. Burgdorfer W, Barbour AG, Hayes SF, Peter 0, Aeschlimann A: Lyme disease-a tick-borne
spirochetosis? Science 216:1317-1319, 1982
4. Johnson RC, Schmid FW, Hyde FW, Steigerwalt AG: Borrelia burgdorferi sp. nov.: Etiologic agent of
Lyme disease. Int J Syst Bacteriol 34:496-497, 1984
5. Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ, Newman JH, Rahn DW, Sigal LH, Spieler
PN, Stenn KS, Malawista SE: The early clinical manifestations of Lyme disease. Ann Int Med
99:76-82, 1983
6. Steere AC, Malawista SE, Bartenhagen NH, Spieler PN, Newman JH, Rahn DW, Hutchinson GJ,
Green J, Snydman DR, Taylor E: The clinical spectrum and treatment of Lyme disease. Yale J Biol
Med 57:453-461, 1984
7. Pachner AR, Steere AC: Neurological findings of Lyme disease. Yale J Biol Med 57:481-483, 1984
8. Pachner AR, Steere AC: The triad of neurologic manifestations of Lyme disease: Meningitis, cranial
neuritis, and radiculoneuritis. Neurology 35:47-53, 1985
9. Reik L, Burgdorfer W, Donaldson JO: Neurologic abnormalities in Lyme disease without erythema
chronicum migrans. Am J Med 81:73-78, 1986
10. Steere AC, Batsford WP, Weinberg M: Lymecarditis: Cardiac abnormalities ofLyme disease. Ann Int
Med 93:8-16, 1980
11. Marcus LC, Steere AC, Duray PH, Anderson AE, Mahoney EB: Fatal pancarditis in a patient with
coexistent Lyme disease and babesiosis. Ann Int Med 103:374-376, 1985
12. Russell H, Sampson JS, Schmid GP, Wilkinson HW, Plikaytis B: Enzyme-linked immunosorbent assay
and indirect immunofluorescence assay for Lyme disease. J Infect Dis 149:465-470, 1984
13. Craft JE, Grodzicki RL, Steere AC: Antibody response in Lyme disease: Evaluation ofdiagnostic tests.
J Infect Dis 149:789-795, 1984
14. Wilkinson HW: Immunodiagnostic tests for Lyme disease. Yale J Biol Med 57:567-572, 1984
15. Magnarelli LA, Anderson JF, Johnson RC: Cross-reactivity in serologic tests for Lyme disease and
other spirochetal infections. J Infect Dis 156:183-188, 1987
16. Rhodes VJ: An epidemiologic study ofmorbidity in Lymedisease (Dissertation). Storrs, CT, University
ofConnecticut, 1988, 58 pp
17. Steere AC, Broderick TF, Malawista SE: Erythema chronicum migrans and Lyme arthritis; epidemio-
logic evidence for a tick vector. Am J Epidemiol 108:312-321, 1978
18. Magnarelli LA, Meegan JM, Anderson JF, Chappell WA: Comparison of an indirect fluorescent-
antibody test with an enzyme-linked immunosorbent assay for serological studies of Lyme disease. J
Clin Microbiol 20:181-184, 1984
19. Anderson JF, Magnarelli LA, Burgdorfer W, Barbour AG: Spirochetes in Ixodes dammini and
mammals from Connecticut. Am J Trop Med Hyg 32:818-824, 1983262 PETERSEN ET AL.
20. Magnarelli LA, Anderson JF: Early detection and persistence ofantibodies to Borrelia burgdorferi in
persons with Lyme disease. Zbl Bakt Hyg 263:392-399, 1988
21. SAS Institute Inc: SAS User's Guide: Statistics, version 5 edition. Cary, NC, SAS Institute Inc, 1985
22. State of Connecticut Department of Health Services: Annual Registration Report of Vital Statistics,
1984. Hartford, CT, State ofConnecticut Department of Health Services, 1985
23. Kaslow RA,SamplesCL,Simon DG, LewisJN:Occurrenceoferythema chronicum migransand Lyme
disease among children in two noncontiguous Connecticut counties. Arthritis Rheum 24:1512-1516,
1981
24. Wallis RC, Brown SE, Kloter KO: Erythema chronicum migrans and Lyme arthritis: Field study of
ticks. Am J Epidemiol 108:322-327, 1978
25. Magnarelli LA, Anderson JF, Shaw E, et al: Borreliosis in equids in northeastern United States. Am J
Vet Res 49:359-362, 1988
26. Magnarelli LA, Anderson JF, Chappell WA: Geographic distribution of humans, racoons, and
white-footed mice with antibodies to Lyme disease spirochetes in Connecticut. Yale J Biol Med
57:619-626, 1984
27. Steere AC, Taylor E, Wilson ML, Levine JF, Spielman A: Longitudinal assessment ofthe clinical and
epidemiological features of Lyme disease in a defined population. J Infect Dis 154:295-300, 1986
28. Shrestha M, Grodzicki RL, Steere AC: Diagnosing early Lyme disease. Am J Med 78:235-240, 1985